Price T Rowe Associates Inc. MD Lowers Holdings in Guardant Health, Inc. (NASDAQ:GH)

Price T Rowe Associates Inc. MD trimmed its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 88.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,404 shares of the company's stock after selling 746,104 shares during the period. Price T Rowe Associates Inc. MD owned 0.08% of Guardant Health worth $2,946,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its position in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after purchasing an additional 230 shares in the last quarter. Summit Investment Advisors Inc. grew its position in shares of Guardant Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock worth $377,000 after purchasing an additional 391 shares in the last quarter. Arizona State Retirement System raised its stake in Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after purchasing an additional 403 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after buying an additional 817 shares in the last quarter. Finally, Fiduciary Alliance LLC grew its holdings in shares of Guardant Health by 7.6% during the 4th quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock valued at $363,000 after purchasing an additional 836 shares during the last quarter. Institutional investors own 92.60% of the company's stock.

Analyst Ratings Changes

GH has been the topic of several recent analyst reports. Morgan Stanley boosted their target price on shares of Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a report on Thursday, March 6th. The Goldman Sachs Group upped their price objective on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Barclays lifted their price target on Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, May 1st. UBS Group raised their price target on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Finally, Stifel Nicolaus lifted their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $52.32.

Guardant Health Stock Up 0.1 %

GH traded up $0.04 during midday trading on Friday, hitting $41.72. 2,781,560 shares of the company traded hands, compared to its average volume of 2,231,425. The company's 50-day moving average is $43.72 and its 200 day moving average is $38.84. The firm has a market capitalization of $5.17 billion, a PE ratio of -11.72 and a beta of 1.49. Guardant Health, Inc. has a 52 week low of $18.01 and a 52 week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. The firm's revenue for the quarter was up 20.8% compared to the same quarter last year. On average, sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the transaction, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. This trade represents a 4.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders sold 107,132 shares of company stock worth $5,249,355. 5.50% of the stock is owned by insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.